Lilly's Lechleiter sees pharma clouds abroad

Eli Lilly ($LLY) CEO John Lechleiter (photo) says price squeezes in Europe and Japan will be key challenges to his company's sales in 2012, one week after the company predicted a bigger-than-expected decline in profits this year. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.